CollPlant Biotechnologies Ltd (CLGN) carries a Roarable Rating of D (Sell) with 50/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
FRED Regime × Technicals: 9% of 52W Range • RSI-14 at 56.3 (BULLISH MOMENTUM)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While CLGN currently carries a cautious 50/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.69) and Max Pain ($4.62) forces dealer call-delta covering toward $24.04.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
CollPlant Biotechnologies Ltd (CLGN) surged +11.39% to $4.40, trading at 9% of its 52-week range ($2.64 – $22.9). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) today announced that its subsidiary LightSolver Ltd. ("LightSolver"), a pioneer of pure photonic computing and developer of the Laser Processing Unit (LPU)™, has
The Israel Ministry of Defense Engagement Strengthens LightSolver’s Position in the Emerging Photonic Computing Market for Defense Applications, Estimated at Up to $5 Billion AnnuallyRehovot, Israel, Oct. 29, 2026 (GLOBE
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CLGN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CLGN. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, CollPlant Biotechnologies Ltd (CLGN) ranks #353 by composite RQD confidence (50/100, grade D) and #873 by equity capitalization ($12.7M). Within this direct 5-issuer industry benchmark cohort, CLGN leads on earnings valuation at N/A trailing P/E, while CLGN leads on capital efficiency and profitability with -35.0% ROIC and 64.8% gross margin. CLGN currently leads its immediate peer cohort in composite quantitative strength at 50/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CLGN
ACTIVE
CollPlant Biotechnologies Ltd | D | 50/100 | — | 64.8% | -35.0% | +11.39% | $12.7M | Benchmark Subject |
| CUPR Cuprina Holdings (Cayman) Limited (Class A) | E | 32/100 | — | -1.3% | -35.0% | -1.07% | $14.1M | /cupr-vs-clgn → |
| LFWD Lifeward Ltd. | D | 46/100 | — | 96.0% | -35.0% | +2.78% | $16.7M | /lfwd-vs-clgn → |
| RGNT Regentis Biomaterials Ltd. | D | 44/100 | — | — | -35.0% | +10.57% | $9.6M | /rgnt-vs-clgn → |
| HSCS HeartSciences Inc. | D- | 43/100 | — | 59.1% | -35.0% | +7.12% | $17.5M | /hscs-vs-clgn → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), CollPlant Biotechnologies Ltd (CLGN) reported GAAP revenue of $2.4M (+360.4% vs. FY2024 revenue of $515.0K , and -78.4% cumulative change since FY2023) , GAAP net income of -$11.5M, operating cash flow of -$9.4M, and free cash flow of -$9.4M (+35.2% YoY). On the balance sheet, CLGN closed FY2025 with $10.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $2.4M | -$11.5M | -$9.4M | -$9.4M | $10.8M | — |
| FY2024 (FY) | 2024-12-31 | $515.0K | -$16.6M | -$14.1M | -$14.6M | $18.7M | — |
| FY2023 (FY) | 2023-12-31 | $11.0M | -$7.0M | -$2.8M | -$2.8M | — | — |
As of 2026-11-01, CollPlant Biotechnologies Ltd (NASDAQ: CLGN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $4.40 (+11.39% 1D, market cap $12.7M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CLGN ranks #353 in composite RQD confidence.
Within the Health Care sector (Industrial Specialties), CLGN carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of 64.8%, and ROIC of -35.0%. By comparison, CUPR (Cuprina Holdings (Cayman) Limited (Class A)) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $14.1M) and LFWD (Lifeward Ltd.) posts a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $16.7M). Among the 5-stock peer group, CLGN leads on earnings multiple (N/A) while CLGN leads on capital efficiency (-35.0% ROIC).
Per CLGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001631487), CollPlant Biotechnologies Ltd generated $2.4M in revenue (+360.4% YoY), -$11.5M in net income, and -$9.4M in free cash flow against $10.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
CLGN last traded at $4.40 (+11.39% on volume of 167,112 shares), positioning the stock +19.24% above its 50-day simple moving average ($3.69) and -13.89% below its 200-day simple moving average ($5.11). Across its 52-week range of $2.64 to $22.90, CLGN sits at the 8.7% percentile with a 14-day RSI of 56.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($3.85 to $4.95).
Why CLGN Stock surged +11.39% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.